THE COMPARISON OF THREE REAL-TIME PCR KITS FOR SARS-COV-2 DIAGNOSIS 1 2 **REVEALS DISCREPANCIES ON THE IDENTIFICATION OF POSITIVE COVID-19 CASES** 3 AND DISPERSION ON THE VALUES OBTAINED FOR THE DETECTION OF SARS-COV-2 4 VARIANTS

5

6 Álvaro Santibáñez^{1,6}¶, Roberto Luraschi¹¶, Carlos Barrera-Avalos¹¶, Eva Vallejos-Vidal^{1,2}, Javiera Alarcón¹, Javiera Cayunao¹, Andrea Mella¹, Maximiliano Figueroa¹, Felipe Hernández¹, Bárbara 7 Plaza¹, Ailen Inostroza-Molina¹, Daniel Valdés^{1,3}, Mónica Imarai^{1,3}, Claudio Acuña-Castillo^{1,3}, Felipe E. Reyes-López^{1,4,5,*}, Ana María Sandino^{1,3,*}. 8

- 9
- 10 ¹ Centro de Biotecnología Acuícola, Facultad de Química y Biología, Universidad de Santiago de 11 Chile, Santiago, Chile.
- 12 ² Centro de Nanociencia y Nanotecnología CEDENNA, Universidad de Santiago de Chile.
- ³ Department of Biology, Faculty of Chemistry and Biology, University of Santiago de Chile, 13 14 Santiago, Chile.
- 15 ⁴ Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain. 16
- 17 ⁵ Facultad de Medicina Veterinaria y Agronomía, Universidad de Las Américas, Santiago, Chile.
- 18 ⁶Programa Disciplinario de Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina,
- Universidad de Chile, Santiago, Chile. 19
- 20 ¶: These authors contributed equally to this work

21 * Corresponding author: Felipe.Reyes@uab.cat; felipe.reyes.l@usach.cl (Felipe E. Reyes-López) ana.sandino@usach.cl (A.M. Sandino) 22

23 ABSTRACT

24 The COVID-19 pandemic has generated a huge challenge and threat to public health throughout the 25 world population. Reverse transcription associated with real-time Polymerase Chain Reaction (RT-26 qPCR) has been the gold-standard molecular tool for diagnosis and detection of the SARS-CoV-2. 27 Currently, it is used as the main strategy for testing, traceability, and control of positive cases For this reason, the on-top high demand for reagents has produced stock-out on several occasions and 28 the only alternative to keep population diagnosis has been the use of different RT-qPCR kits. 29 30 Therefore, we evaluate the performance of three of the commercial RT-qPCR kits currently in use 31 for SARS-CoV-2 diagnosis in Chile, consisting in: TaqMan 2019-nCoV Assay Kit v1 (Thermo). 32 Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 (BGI), and LightCycler® Multiplex RNA Virus Master (Roche). Results of quantification cycle (Cq) and relative 33 fluorescence units (RFU) obtained from their RT-qPCR reactions revealed important discrepancies 34 35 on the total RNA required for the identification of SARS-CoV-2 genes and diagnosis. Marked 36 differences between kits in samples with 30>Cq value< 34 was observed. Samples with positive 37 diagnoses for Covid-19 using the Thermo Fisher kit had different results when the same samples were evaluated with Roche and BGI kits. The displacement on the Cq value for SARS-CoV-2 38 39 identification between the three different RT-qPCR kits was also evident when the presence of 40 single nucleotide variants was evaluated in the context of genomic surveillance. Taken together, this 41 study emphasizes the special care adjusting RT-qPCR reaction conditions of the different kits must be taken by all the laboratories before carrying out the detection of SARS-CoV-2 genes from total 42

43 RNA nasopharyngeal swab (NPS) samples.

- 44 Keywords: SARS-CoV-2 genomic surveillance; COVID-19 diagnosis; false-negative RT-qPCR
- 45 cases; SARS-CoV-2 variants detection; SARS-CoV-2 genomic surveillance.

46 **1. INTRODUCTION**

47 Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome 48 coronavirus 2 (SARS-CoV-2). Since it was declared a pandemic by the World Health Organization 49 (WHO) on March 11, 2020 [1], it has generated a huge challenge and threat to public health 50 throughout the world population. This has forced governments to take a series of health measures to 51 control its spread, which mainly depend on the effective and timely diagnosis of infected people [2]. 52 The Reverse transcription associated with real-time Polymerase Chain Reaction (RT-qPCR) has 53 been the gold-standard molecular tool for diagnosis and detection of the SARS-CoV-2 virus 54 recommended and, consequently, the most used strategy for testing, traceability, and isolation of 55 positive cases at present [3]. For this reason, it is not a surprise the use of supplies and kits for the 56 performance of this technique in diagnostic laboratories has increased [4]. To provide the supply 57 chain, a series of RT-qPCR kits for SARS-CoV-2 detection have been manufactured and are 58 currently available on market. Because the on-top high demand for reagents, in many opportunities 59 on which there have been situations of stock-out, the only alternative to maintain the diagnosis of 60 the population has been the use of alternative RT-qPCR kits. Thus, it is essential to analyze, 61 compare and clinically validate the performance of these commercial detection kits, to guide an 62 accurate diagnosis for this and other emerging infectious diseases.

63 The diagnosis of COVID-19 has been based on the detection of a series of target viral genes used 64 most frequently for the detection of SARS-CoV-2 by means of the RT-qPCR technique. For 65 example, the detection includes viral RNA of structural proteins such as envelope (E), nucleocapsid 66 (N) and spike (S) and a large open reading frame 1ab (ORF1ab), which encode non-structural 67 proteins, such as RNA-dependent RNA polymerase (RdRp) [5]. Along these lines, Van Kasteren P, 68 et al 2020, demonstrated and compared the performance of a series of commercially available RTqPCR Kits, which detect, for example, RdRp and S protein (KH Medical Kit) or ORF1ab and N 69 70 protein (CerTest Biotec Kit) with \geq 96% detection efficiency [6]. On the other hand, Kyu-Hwa H et 71 al, 2020, reported a comparison of commercial RT-qPCR Kits approved by emergency use in 72 Korea, which mainly detected E, N and RdRp proteins, with different detection specificity[7]. However, despite the publications on the RT-qPCR Kit analysis found in the market for the 73 74 diagnosis of COVID19, it is still essential to clinically validate those that have not been considered 75 to date, even in their performance in the detection of viral variants such as B.1.1.7 (Alpha), B.1.351 76 (Beta) and P.1 (Gamma) variants.

77 In this work we evaluate the performance of three commercial RT-qPCR kits for SARS-CoV-2 78 diagnosis, including TaqMan 2019-nCoV Assay Kit v1 (Thermo Fisher), the Real-Time Fluorescent 79 RT-PCR Kit for Detecting SARS-CoV-2 (BGI), and the LightCycler® Multiplex RNA Virus 80 Master (Roche). We report differences in the Cq values and RFU between kits on both, the 81 reference control and SARS-CoV-2 target genes. We also assessed the impact of the COVID-19 82 diagnosis upon the detection of SARS-CoV-2 single nucleotide variants. Our results highlight the 83 relevance to adjust RT-qPCR reaction conditions of the different kits by all the laboratories before 84 carrying out the detection of SARS-CoV-2 genes from total RNA extracted from NPS samples.

85 2. MATERIALS AND METHODS

86 **2.1 Samples.** Nasopharyngeal swab samples (NPSs) of clinical patients included in this study, were 87 collected by the Primary Care Centers and the Hospitals that belongs to the Central Metropolitan 88 Health Service (Santiago of Chile) (SSMC by its acronym in Spanish). The swab samples were 89 taken, preserved and transported using the Genosur sampling and transport kit (catalog number: 90 DM0001VR; Genosur LLC, NW) that contains an RNA stabilization buffer called DNA/RNA 91 Shield (Zymo Research Corp. Irvine, CA) that immediately provoke virus inactivation potentially 92 present in the sample. All the samples arrived at the laboratory before the first 24 hours after the 93 sampling collection. These samples were processed in the laboratory of Virology (University of

Santiago of Chile, USACH) in our role of laboratory of SARS-CoV-2 diagnostics that was member
 of the University laboratories network developed in Chile for increasing the diagnostic capacity at

96 national level.

97 2.2 Total RNA extraction. Total RNA extraction was carried out using the Total RNA purification 98 kit (96 deep well plate format; Norgen Biotek Corp; Canada). Briefly, 250 µL of NPS from each 99 patient was collected in a 1.5 ml tube and vortexed with 500 µL of lysis buffer (buffer RL: absolute 100 ethanol; 1:1) during 1 min. Then, the solution was centrifuged at 14,000 x g for 5 min at room temperature. Subsequently, 700 µL of the lysate was transferred to a 96-filter plate and centrifuged 101 102 at 1690 x g for 6 min. The 96-filter plate was washed twice with 400 μ L of wash solution A. After 103 each wash the plate was centrifuged at 1690 x g for 4 min. Then, the plate was centrifuged at 1690 x 104 g for 10 min to any volume trace. Finally, the total RNA was eluted using 70 μ L of Elution solution 105 A and centrifuged at 1690 x g for 7 min. The purified RNA was evaluated immediately by RT-PCR.

106 2.3 SARS-CoV-2 detection by RT-qPCR. Three different kits for the SARS-CoV-2 detection 107 were evaluated. The detection of viral SARS-COV-2 genome sequence was carried out using the 108 ORF1ab probe (TaqMan[™] 2019nCoV Assay Kit v1 (Thermo Fisher Scientific, Cat. No. A47532)) 109 using a one-step strategy. Positive internal control probes for ORF1ab and RNase P (TagManTM 2019-nCoV Control Kit v1; Thermo Fisher Scientific, Cat. No. A47533) were included and 110 assessed individually in the 96-well PCR plate. The polymerase from TaqMan[™] Fast Virus 1-Step 111 112 Master Mix (Applied BiosystemsTM, Cat. No. 44-444-36) was included in each reaction. Each 113 reaction contained 5 µl of TaqMan[™] Fast Virus 1-Step Master Mix 4X, 1 µl of ORF1ab assay 20X 114 (FAM detector channel), 1 µl of RNase P assay 20X (HEX detector channel), 11 µl of nuclease-free 115 water, and $2 \mu l$ of extracted RNA sample. When 5 μl of extracted RNA was used as template, $8 \mu l$ of nuclease-free water were dispensed in the reaction. The amplification thermal conditions include 116 117 the reverse transcription at 50 °C for 5 minutes, predenaturation at 95 °C for 20 s, followed by 45 cycles at 95 °C for 3 seconds and 60 °C for 30 seconds. The BGI kit detects viral SARS-COV-2 118 119 genome sequence using the ORF1ab probe (Real-Time Fluorescent RT-PCR Kit for Detecting 120 SARS-CoV-2 (BGI Health (HK) Co. Ltd, China, Cat. No. MFG030010)) using a one-step strategy. 121 Positive internal control probes for ORF1ab and β -actin were included and assessed individually in 122 the 96-well PCR plate. The polymerase from BGI Reaction Mix (BGI Health (HK) Co. Ltd, China, Cat. No. MFG030010) was included in each reaction. Each reaction contained 18.5 µl of SARS-123 124 CoV-2 Reaction Mix (HEX detector channel to β -actin and FAM detector channel to ORF1ab), 1.5 125 ul SARS-CoV-2 Enzyme Mix, 8 ul of nuclease-free water, and 2 ul of extracted RNA sample. 126 When 10 µl of extracted RNA was used as template, nuclease-free water was not dispensed in the 127 reaction. The amplification thermal conditions include the reverse transcription at 50 °C for 5 128 minutes, predenaturation at 95 °C for 20 s, followed by 45 cycles at 95 °C for 3 seconds and 60 °C for 30 seconds. The LightCycler[®] Multiplex RNA Virus Master kit detects viral SARS-COV-2 129 genome sequence using the RdRP probe (LightMix[®] Modular Wuhan CoV RdRP-gene. Cat. No. 130 53-0777-96) using a one-step strategy. Positive internal control probe for RdRP (LightMix[®] 131 132 Modular Wuhan CoV RdRP-gene. Cat. No. 53-0777-96) was included and assessed individually in 133 the 96-well PCR plate. As reference control, the RNase P probe (TaqMan[™] 2019-nCoV Control 134 Kit v1; Thermo Fisher Scientific, Cat. No. A47533) was included for ensuring the presence of total 135 RNA extracted from NPS samples as template. This decision was supported on the antecedent the Roche RT-qPCR kit utilized the Equine Arteritis Virus (EAV) as an internal control for the 136 137 extraction process but not a control of the total RNA extracted. The polymerase from RT-qPCR Reaction Mix 5x (The LightCycler[®] Multiplex RNA Virus Master kit, Cat. No. 06754155001) was 138 included in each reaction. Each reaction contained 0.5 µl of RdRP (FAM detector channel), 4µl of 139 140 RT-qPCR Reaction Mix 5x, 0.1 µL of RT Enzyme Solution 200x, 1 µL of RNase P probe, 12.4 µl 141 of nuclease-free water, and 2 µl of extracted RNA sample. When 5 µl of extracted RNA was used 142 as template, 9.4 µl of nuclease-free water were dispensed in the reaction. The amplification thermal 143 conditions include the reverse transcription at 50 °C for 10 minutes, predenaturation at 95 °C for 30

s, followed by 45 cycles at 95 °C for 5 seconds and 60 °C for 30 seconds. All the RT-qPCR
reactions were performed on the Agilent AriaMx Real-Time PCR System (Agilent Technologies,
Part. No. G8830A). Data and graphics were extracted using the Agilent AriaMx software.

147

148 2.4 PCR efficiency and detection limit

To establish PCR efficiency and the detection limit for both the reference (RNase P for Thermo 149 150 Fisher and Roche RT-qPCR kits; beta-actin for BGI kit) and the viral genes assessed (ORF1ab for 151 Thermo Fisher and BGI kits; RdRP for Roche kit) we ran RT-qPCR reactions using serial dilutions. 152 In order to get the maximum representation of values in the curve, we used for the 10-fold serial 153 dilutions a reference pool made from randomized ten total RNA NPS-extracted samples with a Cq 154 value around 20. The reactions were carried out in triplicate according to the specific conditions indicated by the manufacturer and described above. All the RT-qPCR reactions were performed on 155 156 the Agilent AriaMx Real-Time PCR System. We determined the slope by linear regression in 157 GraphPad Prism and defined the required levels for PCR efficiency (E) and R-squared (R^2) as>95 158 % and>0.95, respectively. The primer efficiency was calculated according to the formula Efficiency % (E) = $(10^{(-1/\text{Slope})-1})$ x 100 [8]. To determine an approach about the detection limit we select ten 159 samples with Cq values above 30. To determine the minimum detection limit for each RT-qPCR 160 SARS-CoV-2 detection kit, a standard curve for the amplification of each probe assessed was 161 generated. The detection limit was established based on the last dilution on all the triplicates 162 amplified. We also took into consideration the R^2 (intended as a goodness-of-fit measure for linear 163 regression) and the probe efficiency (closer to 100%, intended 100% as the optimum probe 164 165 efficiency value).

166 2.5 SARS-CoV-2 variants detection. The detection of different variants was made by the 167 AccuPower® SARS-CoV-2 Variants ID Real-Time RT-PCR kit (Bioneer Cat. No. SMVR-2112) 168 according to manufacturer conditions as described elsewhere [9]. The Exicvcler 96 V4 Real Time 169 thermal cycler (Bioneer) was used for detecting fluorescence on the TET, TexasRed, FAM, 170 TAMRA and Cyanine5 channels. Briefly, the reaction mix was prepared using 5 µL of Oligo Mix 1 171 (ID 1, which detects conventional SARS-CoV-2, the Hv69 / 70 DEL and N501Y mutation) or 5 μ L of Oligo Mix 2 (ID2, which detects the P681H mutation, E484K and K417N/T), 5 uL of Enzyme 172 173 Mix and 8 μ L of nuclease-free water. Subsequently, to the 18 μ L of Reaction Mix containing Oligo 174 Mix 1 or Oligo Mix 2, 2 µL of RNA extracted from samples routinely collected from COVID-19 175 positive patients were added. The thermal profile consists of a reverse transcription phase for 15 176 minutes at 50 ° C and an activation phase at 95 ° C for 5 minutes. Then, for PCR reaction 45 amplification cycles were run with a denaturation phase for 5 seconds at 95°C, an annealing / 177 178 extension phase for 30 seconds at 57°C and a scan phase within each cycle for the different probes. 179 The data obtained was exported in an Excel spreadsheet and the Cq value and fluorescence relative 180 intensity was analyzed for the internal positive control, IPC (TAMRA) and each one of the variants 181 assessed.

182 **2.6 Ethics statement.** All the experimental procedures included in this study was authorized by the 183 Ethical Committee of the University of Santiago of Chile (No. 226/2021) and the Scientific Ethical 184 Committee of the Central Metropolitan Health Service, Ministry of Health, Government of Chile 185 (No. 370/2021), and following the Chilean law in force. Patients interested in knowing their 186 diagnosis of the presence of SARS-CoV-2 were notified verbally in the same Family Health Center 187 (CESFAM, for its acronym in Spanish; Central Metropolitan Health Service, Ministry of Health, 188 Government of Chile) to which they attended on their own. Verbal consent was detailed by the 189 health professional assigned by CESFAM for this purpose. Once their consent was given, the 190 patient gave their data to the health professional to identify, trace, and isolate a possible positive 191 case of Covid-19. Once the sample was received in the diagnostic laboratory, the person in charge 192 of the sample reception team (Dr. Claudio Acuña-Castillo) assigned an internal sample code to

ensure the traceability of the sample. Thus, data analysis used for this study was conducted only using the internal sample code numbers assigned at the moment to receive the nasopharyngeal swab samples for diagnostics purpose. Accordingly, the samples have been irreversible anonymized for analysis and interpretation of results by the diagnostic laboratory team. Once assigned the diagnostic result for each sample, Dr. Acuña-Castillo was responsible for communicating the result to the CESFAM of origin for each sample.

2.7 Data representation and statistical analysis. A paired two-sided Student T-test was used to
determine differences between the Cq and RFU obtained from the different SARS-CoV-2 RT-qPCR
detection kits. A *p*-value of □<□0.05 was considered statistically significant. GraphPad Prism 8
statistical software was used to analyze and plot the data obtained.

203

204 **3. RESULTS**

205 The analysis of the extracted NPS samples with the Thermo Fisher RT-qPCR kit using 5 µl 206 (according to the manufacturer instructions) and 2 µl of total RNA revealed important differences 207 both in the quantification cycle (Cq) and in the relative fluorescence units (RFU) determined by the 208 RNase P (reference gene) and ORF1ab (SARS-CoV-2 gene) amplification (Fig 1). From a global 209 perspective, the 2 µl of total RNA template decreased the Cq value in most of the samples assessed compared to the 5 μ l of total RNA template (Fig 1A). This first perception is reinforced when the 210 211 mean \pm SD is represented, showing a lower Cq mean value for the 2 µl of total RNA template (14.09 ± 0.99) than the 5 µl of total RNA template (14.82 ± 0.98) (Fig 1B). The same behavior was 212 also observed for the RFU, registering a strong difference between both volume of templates (Fig 213 214 1C) and determined by a higher mean fluorescence for the 2 μ l of total RNA template (8969 ± 215 1232) than the 5 μ l of total RNA template (4041 ± 981) (Fig 1D). When the presence of SARS-216 CoV-2 genome was evaluated by RT-qPCR in the total RNA extracted from NPS samples, those three samples diagnosed as COVID-19 positive using 5 µl of total RNA showed quite similar Cq 217 values using 2 μ l of total RNA as template (from lower to higher Cq value: Cq_{5ul}= 21.96 and 218 Cq_{2ul}=21.10; Cq_{5ul}= 35.13 and Cq_{2ul}= 36.69; Cq_{5ul}= 36.15 and Cq_{2ul}= 36.53) (Fig 1E). However, 219 220 other three total RNA NPS-extracted samples diagnosed as COVID-19 negative using the 5 µl of total RNA was diagnosed as COVID-19 positive with a template of 2 μ l of total RNA (Cq_{5ul}= 46.00 221 222 and $Cq_{2ul} = 35.18$; $Cq_{5ul} = 46.00$ and $Cq_{2ul} = 36.92$; $Cq_{5ul} = 39.99$ and $Cq_{2ul} = 37.03$). Based on these results, it is not a surprise that the Cq mean for the 2 μ l of total RNA template (36.39 ± 5.02) was 223 224 lower than the 5 μ l of total RNA template (40.44 \pm 7.29) (Fig 1F). In the same way than it was 225 observed for the amplification of the RNase P reference gene, all the total RNA NPS-extracted samples registered a much higher fluorescence for the 2 μ l compared to the 5 μ l of total RNA as 226 227 template (Fig 1G). Thus, the 2 μ l of total RNA triplicated its mean fluorescence value (1705 ± 1553) in comparison with the 5 μ l of total RNA (544.6 ± 562.3) (Fig 1H). The results with Thermo 228 229 Fisher RT-qPCR kit suggest a higher sensitivity of SARS-CoV-2 using 2 µl of total RNA instead 230 the 5 μ l recommended by the manufacturer.

231

232 The BGI RT-qPCR kit registered also differences between the volume recommended by the manufacturer (10 μ l) and 2 μ l of total RNA. At first sight, the amplification of beta-actin (internal 233 control) showed apparently a slight lower Cq values for the 10 µl of total RNA template in most of 234 235 the samples assessed compared to the 2 μ l of total RNA template (Fig 2A). This data is supported 236 by the mean \pm SD of all analyzed samples, effectively showing a slight decrease on the Cq mean 237 value for the 10 μ l of total RNA template (23.21 \pm 1.25) than the 2 μ l of total RNA template (23.58) 238 \pm 1.20) (Fig 2B). By contrast, the opposite trend observed for Cq values was observed for RFU, noting an apparent higher fluorescence when it was used a volume of 2 μ l of total RNA as template 239

240 (Fig 2C). This perception is confirmed by the higher RFU mean using 2 μ l (4216 ± 698.5) than the 241 10 μ l of total RNA template (3724 ± 860.5) (Fig 2D). When the presence of SARS-CoV-2 was 242 evaluated in the total RNA NPS-extracted samples, very similar results were observed between the paired Cq values for 10 and 2 µl of total RNA (Fig 2E). However, four samples diagnosed as 243 244 COVID-19 negative with 10 µl of total RNA were determined as COVID-19 positive when 2 µl of 245 total RNA were dispensed (Cq_{10ul} = 39.66 and Cq_{2ul} = 31.77; Cq_{10ul} = 46.00 and Cq_{2ul} = 35.05; Cq_{10ul} = 46.00 and Cq_{2ul}= 33.54; Cq_{10ul}= 46.00 and Cq_{2ul}= 28.79) (Fig 2F). This result is influencing upon a 246 slight lower Cq mean value for SARS-CoV-2 ORF1ab detection with $2\mu l$ (27.70 ± 7.16) than 10 μl 247 248 (29.64 ± 9.52) . In the same way than it was observed for the amplification of the Beta-actin 249 reference gene, all the total RNA NPS-extracted samples registered a much higher fluorescence for 250 the 2 μ l (4093 ± 1568) compared to the 10 μ l of total RNA as template (2685 ± 1816) (Fig 2G-H). 251 These results with the BGI RT-qPCR kit suggest a higher sensitivity of SARS-CoV-2 using 2 µl of 252 total RNA instead the 10 µl recommended by the manufacturer.

253

254 The Roche RT-aPCR kit registered some differences between the volume recommended by the 255 manufacturer (5 µl) and 2 µl of total RNA, being most of them identified in the SARS-CoV-2 RdRP 256 gene. Looking at the paired Cq values for the RNase P reference gene, the 2 µl of total RNA template showed quite similar Cq values for most of the samples assessed compared to the 5 μ l of 257 258 total RNA template (Fig 3A). In fact, although the RNase P Cq mean value for 2 µl was slightly 259 lower (18.22 \pm 1.76) than 5 μ l of template (18.63 \pm 1.92), no significant differences were observed 260 between them (Fig 3B). The same trend was also observed for the RFU, registering a marked 261 difference between both volume of templates (Fig 3C) and determined by a higher mean fluorescence for the 2 μ l of total RNA template (6351 ± 812) than the 5 μ l of total RNA template 262 263 (4928 ± 849) (Fig 3D). The SARS-CoV-2 RdRP gene amplification showed quite similar paired Cq 264 values in most of the cases evaluated. In fact, seventeen of the twenty-five samples were diagnosed 265 as COVID-19 positive using both 5 μ l and 2 μ l of total RNA (Fig 3E). However, other two total RNA NPS-extracted samples diagnosed as COVID-19 negative using the 5 µl of total RNA was 266 diagnosed as COVID-19 positive using 2 μ l of total RNA as template (Cq_{5ul}= 46.00 and Cq_{2ul}= 267 35.53; Cq_{5ul} = 40.33 and Cq_{2ul} = 31.85) (Fig 3E). This difference in the diagnosis for those two 268 269 samples is probably the main responsible of the slight lower RdPR Cq-value differences registered 270 for the 2 μ l of total RNA template (30.62 ± 6.64) than the 5 μ l of total RNA template (33.02 ± 9.14) (Fig 3F). Similarly to the amplification observed for the RNase P reference gene, it was also 271 observed a higher fluorescence on the amplification for RdRP with 2 μ l compared to the 5 μ l of 272 273 total RNA as template (Fig 3G). Thus, the mean fluorescence for the 2 ul of total RNA was greater 274 (1738 ± 478) than 5 µl of total RNA (1155 ± 580) (Fig 3H). The results with Roche RT-qPCR kit 275 confirm the higher sensitivity of SARS-CoV-2 using 2 µl of total RNA instead the volume 276 recommended by the manufacturer.

277

278 To evaluate the performance of the three RT-qPCR, we compared the Cq, RFU and COVID-19 279 diagnosis on 90 randomized total RNA NPS-extracted samples. The amplification of the reference 280 gene showed clear differences between the RT-qPCR kits assessed, showing a greater Cq value on 281 most of the samples evaluated with the Thermo Fisher kit (Fig 4A). By contrast, the samples amplified with the BGI kit showed the lower Cq value, even identifying two samples behind the 282 beta-actin detection limit (Fig 4A). The differences observed for the RNase P paired data was 283 284 confirmed with the Cq mean value for each kit, noting the highest Cq mean value for the Thermo 285 Fisher kit (16.55 \pm 2.37), followed by the Roche kit (18.28 \pm 2.03), and the BGI kit (28.01 \pm 3.01) 286 (Fig 4B). The same profile was observed for the reference gene paired data amplification (Fig 4C), noting the greatest and the lowest Cq mean values for the Thermo Fisher (7351 \pm 1109) and the 287

288 BGI kits (2416 ± 482), respectively (Fig 4D). Importantly, the amplification profile observed for the 289 reference gene was not the same for the SARS-CoV-2 gene amplification. The paired Cq data 290 showed the greater Cq value for the Thermo Fisher kit but now followed by the BGI instead the 291 Roche kit, although no significant differences were observed between the BGI and the Roche kit 292 because the similar Cq mean value for both kits (29.63 \pm 6.87; 29.94 \pm 6.08) (Fig 4E). Importantly, 293 the differences between the Cq mean value on the viral gene for Thermo Fisher kit (27.24 \pm 5.65) 294 and the other two kits is probably the responsible of the discrepancies observed in the COVID-19 295 positive diagnosis for the samples evaluated (23 positive samples diagnosed by Thermo Fisher; 18 296 positive samples diagnosed by BGI; 17 positive samples diagnosed by Roche) (Fig 4I). At fluoresce 297 level, the paired and mean values showed the same trend than the Cq values, although highlighting 298 the statistical difference also observed between the BGI and Roche RT-qPCR kits (Fig4 G-H).

299 Based on these results, we hypothesize that the discrepancies observed between the RT-qPCR kits 300 evaluated were focused on total RNA NPS-extracted with a high Cq (Cq > 30). Thus, the 301 comparison for the SARS-CoV-2 diagnostic performance was evaluated between the Thermo 302 Fisher, BGI and Roche RT-qPCR kits using ten randomized NPS samples with low Cq value (19< 303 Cq value< 25 for the ORF1ab amplification using the Thermo Fisher RT-qPCR kit), and other ten 304 randomized NPS samples with high Cq value (30< Cq value< 34 for the ORF1ab amplification 305 using the Thermo Fisher RT-qPCR kit). The reference gene amplification showed differences for 306 the paired Cq values between the RT-qPCR kits both for those samples identified with low Cq value 307 and high Cq value (Fig 5A; Fig 5I). Both in the low and high Cq value sample cases, the reference 308 gene amplification was greater for the Thermo Fisher kit (21.56 \pm 1.40; 23.84 \pm 1.04), followed by 309 the Roche kit (22.86 ± 1.54 ; 24.75 ± 1.15), and the BGI kit (28.54 ± 1.03 ; 29.86 ± 1.66) (Fig 5B; 310 Fig 5J). The differences for the paired RFU between kits had the same trend than it was observed 311 for Cq values, although even more marked when the RT-qPCR kit were compared (Fig 5C; Fig 5K). 312 Thus, in those samples with low and high Cq values, the RFU was much greater in the case of 313 Thermo Fisher kit (7455 \pm 734; 7431 \pm 535), followed by the Roche kit (4381 \pm 633; 5093 \pm 695), and the BGI kit (2154 ± 522 ; 1919 ± 228) (Fig 5D; Fig 5L). Importantly, when the amplification of 314 315 the viral gene was evaluated, it was not observed the same trend registered for the reference gene 316 amplification. In fact, in the paired-comparison perspective all the RNA NPS-extracted samples 317 with low and high Cq values showed the greater Cq viral gene amplification for the Thermo Fisher 318 kit but now followed by the BGI and the Roche kit (Fig 5E; Fig 5M). In this way, in the samples 319 with low Cq values, their mean values showed slight but significant differences between kits (22.03 320 \pm 1.67 for Thermo Fisher; 23.69 \pm 2.65 for BGI; 25.39 \pm 3.66 for Roche) (Fig 5F). However, in the 321 case of the samples with high Cq values more marked differences between kits were registered 322 $(31.98 \pm 1.03 \text{ for Thermo Fisher}; 34.27 \pm 1.91 \text{ for BGI}; 43.27 \pm 3.66 \text{ for Roche})$ (Fig 5N). These 323 differences are probably attributable not only to the sensitivity of each kit but also to the number of 324 samples diagnosed as COVID-19 positive. Moreover, meanwhile in the case of samples with low 325 Cq value all the ten samples were reported with COVID-19 diagnosis (Fig 5Q), in the samples with 326 high Cq just all the ten samples were effectively confirmed with COVID-19 positive diagnosis by 327 Thermo Fisher but only seven and even no one sample were diagnosed using the BGI and Rocke 328 kits, respectively (Fig 5N; Fig 5R). The same behavior trend in the RFU was observed for the low 329 and high Cq value samples, both in the paired (Fig 5G; Fig 5O) and RFU mean value obtained (Fig 330 5H; Fig 5P), respectively. These results indicate that the samples with Cq values greater than 30 331 could compromise its COVID-19 diagnosis depending on the kit used for this purpose.

332

To determine the distribution of positive samples and its impact on the detection of single nucleotide polymorphisms (also called single nucleotide variants, SNV) associated to SARS-CoV-2 variants, we evaluated twelve total RNA samples with a Cq value lower than 26. As it was expected, all the twelve samples were identified as SARS-CoV-2 positive samples. However, from

337 the twelve samples only six of them were also positive for the variants N501Y, K417N/T, and 338 E484K, suggesting the presence of the P1 (Gamma) SARS-CoV-2 variant in the 50% of the 339 samples (Fig 6A). By contrast, none of the samples were positive for Hy 69/70 del, and/or P681H. 340 According to our previous evidence, the Cq mean \pm standard deviation (mean \pm SD) for these 341 samples also showed a clear dispersion on the Cq distribution (Fig 6B). In fact, one of the samples 342 identified with the SARS-CoV-2 N501Y, K417N/T, and E484K SNV registered a Cq_{RdRP} value= 29.98 with the Roche RT-qPCR diagnostic kit (Fig 6B). The same sample showed a Cq_{ORF1ab} value= 343 344 25.71 and Cq_{ORF1ab} value= 27.13 for Thermo Fisher and BGI, respectively (Supplementary Fig 2). 345 This evidence suggests that the recommendation for using only samples with Cq < 30 made by the 346 manufacturer should has also in consideration the diagnostic RT-qPCR used for such purpose.

347

348 4. DISCUSSION

349 Prior work has documented comparisons between the efficacy of different commercial PCR 350 kits for the diagnosis of SARS-CoV-2 by RT-qPCR [6,10–12]. Lu et al 2020 [13], for example, compared and analyzed the performance of Sansure and BioGerm, widely used in Liuzhou People's 351 352 Hospital in Guangxi, China, with an effectiveness of 80 and 94% respectively. On the other hand, 353 Eberle et al 2021 [13], compared nine RT-qPCR kits used in viral diagnosis in the city of Bavaria, 354 Germany. Mostly of them reached percentages of sensitivity between 90-100%, while others two 355 kits reported 49% (Fast Track Diagnostics Kit) or 62% (Wells Bio, Inc) of effectiveness with the 356 highest number of false negatives. However, the choice of Kits that have more than one target gene 357 been less susceptible to obtaining false negatives than tests designed to detect a single genetic 358 target, even in the detection of viral variants [14-16]. These studies suggest considering and 359 analyzing the performance of commercial RT-qPCR kits used locally in the analysis of COVID 19. 360 In fact, a poor performance in the diagnosis of SARS-COV-2 can favor the spread of this and other 361 infectious diseases in the future. In Chile, being the country with the most PCR tests performed per 362 million inhabitants in Latin America [17], no standardization, comparative or efficacy studies of 363 commercial RT-qPCR kits used in the mass diagnosis of local SARS-CoV-2, nor in the detection of 364 emerging variants, have been reported. We announces the first clinical validations and comparation 365 of the TaqMan 2019-nCoV Assay Kit v1 (Thermo Fisher), the Real-Time Fluorescent RT-PCR Kit 366 for Detecting SARS-CoV-2 (BGI) and the LightCycler® Multiplex RNA Virus Master (Roche) 367 commercial RT-qPCR Kits used to control the pandemic and diagnostic in the population of Santiago, Chile. The Cq and the RFU obtained from their RT-qPCR reactions revealed important 368 369 discrepancies on the total RNA volume for the identification of SARS-CoV-2 genes and diagnosis. 370 Importantly, those differences had a marked impact on the identification of positive COVID-19 371 cases. Particularly in those samples with a 30> Cq value< 34, from the ten samples with positive 372 diagnostic for COVID-19 using the Thermo Fisher kit, none of them had the same diagnostic when 373 were evaluated with the Roche kit. This evidence reinforces the need to standardize the total RNA 374 loading volume considering the specific conditions for each diagnostic laboratory. While the 375 Thermo Fisher Kit presents better general parameters in the diagnosis, even in the detection of 376 SNV. These findings are related to the evidence reported by Farfán et al, 2020 [18], work in which 377 the Thermo Fisher kit is indicated as a diagnostic gold standard. While some reports describe the 378 performance of in-house RNA SARS-CoV-2 extraction protocols, validating their results with the 379 same kit [19]. Others point out its compatibility to detect SARS-CoV-2 in nasopharyngeal samples 380 without prior RNA extraction [20], corroborating its good performance and sensitivity in viral 381 detection. On the other hand, while the BGI kit has shown a sensitivity of $\geq 95\%$ in other studies 382 [6], we obtained only 70.1%, possibly due to the random selection of positive samples without 383 considering high or low viral loads. Although in our study the Roche kit had lower RFU, high Cq 384 and less sensitivity compared to Thermo Fisher and BGI, studies indicate that Roche has sufficient 385 performance to detect positive cases and over other RT-qPCR kits, such as Cepheid [21] and Certest

386 Biotec SL. Our study reveals important differences between the Thermo Fisher, BGI and the Roche 387 RT-qPCR kit for SARS-CoV-2 diagnostic both in the Cq and the RFU values. In this way, we consider that the fluorescence is also a parameter that should be carefully considered when 388 389 diagnosing a sample. The displacement on the Cq values for the SARS-CoV-2 genome 390 identification on total RNA NPS-extracted samples could not also affect their Covid-19 diagnosis 391 but also could, as consequence, compromise the identification of viral SNV in the context of 392 genomic surveillance. This study is the first that analyzes and compares the sensitivity and 393 performance of the RT-qPCR kits used in Chile and suggests an in-depth analysis of the new 394 commercial kits manufactured for the control of this and future infectious diseases.

395 396

397 5. REFERENCES

- Organization WH. Statement on the second meeting of the International Health Regulations.
 Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) 2021.
 https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of novel-coronavirus-(2019-ncov). (accessed July 8, 2021).
- Younes N, Al-SAdeq DW, Al-Jighefee H, Younes S, Al-Jamal O, Daas HI, et al. Challenges
 in Laboratory Diagnosis of the Novel. Viruses 2020;12:582.
- 405 [3] Barreto HG, de Pádua Milagres FA, de Araújo GC, Daúde MM, Benedito VA. Diagnosing
 406 the novel SARS-CoV-2 by quantitative RT-PCR: variations and opportunities. J Mol Med
 407 2020;98:1727–36. https://doi.org/10.1007/s00109-020-01992-x.
- 408 [4] Kim S min, Hwang YJ, Kwak Y. Prolonged SARS-CoV-2 detection and reversed RT-PCR
 409 results in mild or asymptomatic patients. Infect Dis (Auckl) 2021;53:31–7.
 410 https://doi.org/10.1080/23744235.2020.1820076.
- 411 [5] Lv D, Ying Q, Weng Y, Shen C, Chu J. Dynamic change process of target genes by RT412 PCR testing of SARS-Cov-2 during the course of a Coronavirus Disease 2019 patient. Clin
 413 Chim Acta 2020;506:172–5. https://doi.org/10.1016/j.cca.2020.03.032.
- 414 [6] van Kasteren PB, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den Brandt
 415 A, et al. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. J Clin
 416 Virol 2020;128:104412. https://doi.org/10.1016/j.jcv.2020.104412.
- Hur KH, Park K, Lim Y, Jeong YS, Sung H, Kim MN. Evaluation of Four Commercial Kits
 for SARS-CoV-2 Real-Time Reverse-Transcription Polymerase Chain Reaction Approved
 by Emergency-Use-Authorization in Korea. Front Med 2020;7:1–10.
 https://doi.org/10.3389/fmed.2020.00521.
- 421 [8] Pfaffl MW. A new mathematical model for relative quantification in real-time RT–PCR.
 422 Nucleic Acids Res 2001;29:e45. https://doi.org/10.1093/nar/29.9.e45.
- Young RM, Solis CJ, Barriga-fehrman A, Abogabir C, Álvaro R, Labarca M, et al.
 Smartphone Screen Testing, a novel pre-diagnostic method to identify SARS-CoV-2
 infectious individuals. Elife 2021:e70333. https://doi.org/10.7554/elife.70333.
- Iglói Z, leven M, Abdel-Karem Abou-Nouar Z, Weller B, Matheeussen V, Coppens J, et al.
 Comparison of commercial realtime reverse transcription PCR assays for the detection of
 SARS-CoV-2. J Clin Virol 2020;129:4–6. https://doi.org/10.1016/j.jcv.2020.104510.
- 429 [11] Tastanova A, Stoffel CI, Dzung A, Cheng PF, Bellini E, Johansen P, et al. A Comparative

430 Study of Real-Time RT-PCR–Based SARS-CoV-2 Detection Methods and Its Application
431 to Human-Derived and Surface Swabbed Material. J Mol Diagnostics 2021;23:796–804.
432 https://doi.org/10.1016/j.jmoldx.2021.04.009.

- [12] Zhao J, Zhang Y, Cao B. Journal of Clinical Chemistry and Comparison of the Performance
 of Six SARS-CoV-2 Nucleic Acid Detection Kit in Positive Samples Using RT-PCR
 2021;4:1–5.
- Lu Y, Li L, Ren S, Liu X, Zhang L, Li W, et al. Comparison of the diagnostic efficacy
 between two PCR test kits for SARS-CoV-2 nucleic acid detection. J Clin Lab Anal
 2020;34:1–5. https://doi.org/10.1002/jcla.23554.
- 439 Eberle U, Wimmer C, Huber I, Neubauer-Juric A, Valenza G, Ackermann N, et al. [14] 440 Comparison of nine different commercially available molecular assays for detection of 441 SARS-CoV-2 RNA. Eur Microbiol J Clin Infect Dis 2021;40:1303-8. 442 https://doi.org/10.1007/s10096-021-04159-9.
- [15] U.S. Food and Drug Administration. Genetic Variants of SARS-CoV-2 May Lead to False
 Negative Results with Molecular Tests for Detection of SARS-CoV-2 n.d.
 https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2 (accessed July 8, 2021).
- Kalita D, Deka S. Effectiveness of Different Gene-Target Strategies for SARS-CoV-2
 Screening by RT-PCR and Other Modalities: A Scoping Review. J Med Diagn Meth
 2020;9:298. https://doi.org/10.35248/2168-9784.2020.9.298.
- 451 [17] Burki T. Understanding variants of SARS-CoV-2. Lancet 2021;397:462.
 452 https://doi.org/http://dx.doi.org/10.1016/S0140-6736(21)00298-1.
- 453 [18] Statista. Rate of coronavirus (COVID-19) tests performed in the most impacted countries
 454 worldwide. 2021-06-28 n.d. https://www.statista.com/statistics/1104645/covid19-testing455 rate-select-countries-worldwide/ (accessed July 8, 2021).
- 456 [19] Farfan MJ, Torres JP, O'ryan M, Olivares M, Gallardo P, Lastra J, et al. Optimizing rt-pcr
 457 detection of sars-cov-2 for developing countries using pool testing. Rev Chil Infectol
 458 2020;37:276–80. https://doi.org/10.4067/s0716-10182020000300276.
- [20] Lázaro-Perona F, Rodriguez-Antolín C, Alguacil-Guillén M, Gutiérrez-Arroyo A, Mingorance J, García-Rodriguez J. Evaluation of two automated low-cost RNA extraction protocols for SARS-CoV-2 detection. PLoS One 2021;16:1–10. https://doi.org/10.1371/journal.pone.0246302.
- 463 [21] Cibali E, Wenzel JJ, Gruber R, Ambrosch A. Pooling for SARS-CoV-2-testing: Comparison
 464 of three commercially available RT-qPCR kits in an experimental approach. Clin Chem Lab
 465 Med 2021;59:E243–5. https://doi.org/10.1515/cclm-2020-1375.
- 466
- 467
- 468
- 469
- 470

- 471
- 472
- 473
- 474

475 FIGURES CAPTIONS

476

477 Fig 1. Comparative analysis for the detection of SARS-CoV-2 from nasopharyngeal swab 478 (NPS) samples using RNase P and ORF1ab gene (Thermo Fisher RT-qPCR kit). The 479 comparison was made from the same NPS sample using the recommended volume of extracted 480 RNA (5 µl of total RNA, recommended by the manufacturer; red spots) and 2 µl of total RNA (blue spots). In the graphs, each spot is a different analyzed sample for each volume condition (5 μ l; 2 481 µl). The line linking two spots indicated the paired result obtained for the same sample assessed 482 483 using the two different volume conditions. Samples with Cq = 46 denotes no amplification. (A) Paired quantification cycle (Cq) analysis for the RNase P the amplification values obtained by RT-484 485 qPCR for each sample assessed. (B) Cq mean \pm standard deviation (mean \pm SD) for the RNase P 486 amplification values obtained by RT-qPCR from all the samples evaluated. (C) Paired relative fluorescence unit (RFU) analysis for the RNase P amplification values obtained by RT-qPCR for 487 488 each sample assessed. (D) RFU mean \pm standard deviation (mean \pm SD) amplification of RNase P 489 obtained by RT-qPCR from all the samples evaluated. (E) Paired Cq analysis for the SARS-CoV-2 490 ORF1ab gene amplification values obtained by RT-qPCR for each sample assessed. (F) Cq mean \pm 491 standard deviation (mean \pm SD) SARS-CoV-2 ORF1ab gene amplification obtained by Rt-qPCR 492 from all the samples evaluated. (G) Paired RFU analysis for the SARS-CoV-2 ORF1ab gene 493 amplification values obtained by Rt- α PCR for each sample assessed. (H) RFU mean \pm standard 494 deviation (mean \pm SD) of SARS-CoV-2 ORF1ab gene amplification obtained by RT-qPCR from all 495 the samples evaluated by RT-qPCR. For statistical analysis, paired two-sided Student T-test was 496 applied (n= 83 NPS samples chosen at random). p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.

497

498 Fig 2. Comparative analysis for the detection of SARS-CoV-2 from NPS samples using beta-499 actin and ORF1ab gene (BGI RT-qPCR kit). The comparison was made from the same NPS 500 sample using the recommended volume of extracted RNA (10 μ l of total RNA, recommended by 501 the manufacturer; red spots) and 2 μ l of total RNA (blue spots). In the graphs, each spot is a 502 different analyzed sample for each volume condition (10 μ l; 2 μ l). The line linking two spots 503 indicated the paired result obtained for the same sample assessed using the two different volume 504 conditions. Samples with Cq = 46 denotes no amplification. (A) Paired quantification cycle (Cq) 505 analysis for the beta-actin amplification values obtained by RT-qPCR for each sample assessed. (B) 506 Cq mean \pm standard deviation (mean \pm SD) for the beta-actin amplification values obtained by RT-507 qPCR from all the samples evaluated. (C) Paired relative fluorescence unit (RFU) analysis for the beta-actin amplification values obtained by RT-qPCR for each sample assessed. (D) RFU mean \pm 508 509 standard deviation (mean ± SD) amplification of beta-actin obtained by RT-qPCR from all the 510 samples evaluated. (E) Paired Cq analysis for the SARS-CoV-2 ORF1ab gene amplification values 511 obtained by RT-qPCR for each sample assessed. (F) Cq mean \pm standard deviation (mean \pm SD) 512 SARS-CoV-2 ORF1ab gene amplification obtained by Rt-qPCR from all the samples evaluated. (G) 513 Paired RFU analysis for the SARS-CoV-2 ORF1ab gene amplification values obtained by RT-514 qPCR for each sample assessed. (H) RFU mean \pm standard deviation (mean \pm SD) of SARS-CoV-2 515 ORF1ab gene amplification obtained by RT-qPCR from all the samples evaluated by RT-qPCR. For

statistical analysis, paired two-sided Student T-test was applied (n= 71 NPS samples chosen at random). * p<0.05; ** p<0.01; *** p<0.001; **** p<0.001.

- 518
- 519
- 520
- 521

522 Fig 3. Comparative analysis for the detection of SARS-CoV-2 from NPS samples using RNase 523 P (as cellular reference gene) and RdRP gene (Roche RT-qPCR kit). The comparison was made 524 from the same NPS sample using the recommended volume of extracted RNA (5 µl of total RNA, 525 recommended by the manufacturer; red spots) and 2 µl of total RNA (blue spots). In the graphs, 526 each spot is a different analyzed sample for each volume condition (5ul; 2 ul). The line linking two 527 spots indicated the paired result obtained for the same sample assessed using the two different 528 volume conditions. Samples with Cq = 46 denotes no amplification. (A) Paired quantification cycle 529 (Cq) analysis for the RNase P the amplification values obtained by RT-qPCR for each sample 530 assessed. (B) Cq mean \pm standard deviation (mean \pm SD) for the RNase P amplification values 531 obtained by RT-qPCR from all the samples evaluated. (C) Paired relative fluorescence unit (RFU) 532 analysis for the RNase P amplification values obtained by RT-qPCR for each sample assessed. (D) 533 RFU mean \pm standard deviation (mean \pm SD) amplification of RNase P obtained by RT-qPCR from 534 all the samples evaluated. (E) Paired Cq analysis for the SARS-CoV-2 RdRP gene amplification values obtained by RT-qPCR for each sample assessed. (F) Cq mean \pm standard deviation (mean \pm 535 536 SD) SARS-CoV-2 RdRP gene amplification obtained by Rt-qPCR from all the samples evaluated. (G) Paired RFU analysis for the SARS-CoV-2 RdRP gene amplification values obtained by RT-537 538 qPCR for each sample assessed. (H) RFU mean \pm standard deviation (mean \pm SD) of SARS-CoV-2 539 RdRP gene amplification obtained by RT-qPCR from all the samples evaluated. For statistical 540 analysis, paired two-sided Student T-test was applied (n= 90 NPS samples chosen at random). * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 541

542

543 Fig 4 Comparative analysis for the detection of SARS-CoV-2 from NPS samples chosen at 544 random using the three RT-qPCR kits. The comparison was made from the same NPS sample 545 using the optimized volume of total RNA extracted (2 μ l). In the graphs, each spot for each RT-546 aPCR kit is a different analyzed sample. The line linking the spots indicated the paired result 547 obtained for the same sample assessed by the different RT-qPCR kits. Samples with Cq= 46 denotes 548 no amplification. (A) Paired quantification cycle (Cq) analysis for the RNase P amplification values 549 obtained by RT-qPCR for each sample assessed. (B) Cq mean \pm standard deviation (mean \pm SD) for 550 the RNase P amplification obtained by RT-qPCR for all the samples evaluated. On (A) and (B), the 551 horizontal red (for Thermo Fisher), blue (for BGI), and green line (for Roche) indicates the 552 detection limit for the determination of the reference gene on each of the RT-qPCR kits (determined 553 on Supplementary Figure 1). (C) Paired relative fluorescence unit (RFU) analysis for the RNase P 554 amplification values obtained by RT-qPCR for each sample assessed. (D) RFU mean ± standard 555 deviation (mean \pm SD) for the RNase P amplification obtained by RT-qPCR from all the samples 556 evaluated. (E) Paired Cq analysis for the SARS-CoV-2 ORF1ab gene amplification values obtained 557 by RT-qPCR for each sample assessed. (F) Cq mean \pm standard deviation (mean \pm SD) for the 558 SARS-CoV-2 gene amplification obtained by each one of the RT-qPCR assessed. On (E) and (F), 559 the horizontal red (for Thermo Fisher), blue (for BGI), and green line (for Roche) indicates the 560 detection limit for the determination of the viral gene on each of the RT-qPCR kits (determined on 561 Supplementary Figure 1). (G) Paired RFU analysis for the SARS-CoV-2 ORF1ab gene

amplification values obtained by RT-qPCR for each sample assessed. (H) RFU mean \pm standard deviation (mean \pm SD) for the SARS-CoV-2 ORF1ab gene amplification obtained by RT-qPCR for all the samples evaluated. (I) NPS samples with COVID-19 positive diagnostic obtained by each one of the RT-qPCR kits assessed. For statistical analysis, paired two-sided Student T-test was applied (n= 90 NPS samples chosen at random). * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.

567

568

569 Fig 5. Comparative analysis for the detection of SARS-CoV-2 from NPS samples with Cq< 25 570 as samples with low Cq value and 30 < Cq < 35 as samples with high Cq value using the three 571 **RT-qPCR kits.** The comparison was made from the same NPS sample using the optimized volume 572 of total RNA extracted (2 µl). In the graphs, each spot for each RT-qPCR kit is a different analyzed 573 sample. The line linking the spots indicated the paired result obtained for the same sample assessed 574 by the different RT-qPCR kits. Samples with Cq= 46 denotes no amplification. (A) Paired 575 quantification cycle (Cq) analysis for the RNase amplification values obtained by RT-qPCR from 576 samples evaluated with low Cq value. (B) Cq mean \pm standard deviation (mean \pm SD) for the 577 RNase P amplification obtained by RT-qPCR from samples evaluated with low Cq value. (C) 578 Paired relative fluorescence unit (RFU) analysis for the RNase P amplification values obtained by 579 RT-qPCR for each sample evaluated with low Cq value. (D) RFU mean ± standard deviation (mean 580 \pm SD) for the RNase amplification obtained by RT-qPCR from samples evaluated with low Cq 581 value. (E) Paired Cq analysis for the SARS-CoV-2 gene amplification (ORF1ab for Thermo Fisher 582 and BGI; RdRP for Roche) obtained by RT-qPCR from the samples evaluated with low Cq value. 583 (F) Cq mean \pm standard deviation (mean \pm SD) for the viral gene amplification values obtained by 584 RT-qPCR from samples evaluated with low Cq value. (G) Paired relative fluorescence unit (RFU) 585 analysis for the viral gene amplification values obtained by RT-qPCR for each sample evaluated 586 with low Cq value. (H) RFU mean \pm standard deviation (mean \pm SD) for the viral gene amplification obtained by RT-qPCR from samples evaluated with low Cq value. (I) Paired 587 588 quantification cycle (Cq) analysis for the RNase amplification values obtained by RT-qPCR from 589 samples evaluated with high Cq value. (J) Cq mean \pm standard deviation (mean \pm SD) for the 590 RNase P amplification obtained by RT-qPCR from samples evaluated with high Cq value. (K) 591 Paired relative fluorescence unit (RFU) analysis for the RNase P amplification values obtained by 592 RT-qPCR for each sample evaluated with high Cq value. (L) RFU mean ± standard deviation (mean 593 \pm SD) for the RNase amplification obtained by RT-qPCR from samples evaluated with high Cq 594 value. (M) Paired Cq analysis for the SARS-CoV-2 gene amplification (ORF1ab for Thermo Fisher 595 and BGI; RdRP for Roche) obtained by RT-qPCR from the samples evaluated with high Cq value. 596 (N) Cq mean \pm standard deviation (mean \pm SD) for the viral gene amplification values obtained by 597 RT-qPCR from samples evaluated with high Cq value. On (M) and (N), the horizontal red (for 598 Thermo Fisher), blue (for BGI), and green line (for Roche) indicates the detection limit for the 599 determination of the viral gene on each of the RT-qPCR kits (determined on Supplementary Figure 600 1). (O) Paired relative fluorescence unit (RFU) analysis for the viral gene amplification values 601 obtained by RT-qPCR for each sample evaluated with high Cq value. (P) RFU mean ± standard 602 deviation (mean \pm SD) for the viral gene amplification obtained by RT-qPCR from samples 603 evaluated with high Cq value. On (M) and (N), the horizontal red (for Thermo Fisher), blue (for 604 BGI), and green line (for Roche) indicates the detection limit for the determination of the viral gene 605 on each of the RT-qPCR kits.(Q) NPS samples with COVID-19 positive diagnostic obtained by the 606 RT-qPCR kits from samples with low Cq value. (R) NPS samples with COVID-19 positive 607 diagnostic obtained by the RT-qPCR kits from samples with high Cq value. For statistical analysis, 608 paired two-sided Student T-test was applied (n= 10 NPS samples with low Cq value; n= 10 NPS samples with high Cq value). * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 609

610

611 Fig 6. Screening and identification of SARS-CoV-2 single nucleotide variants following a RTqPCR strategy. We included twelve total RNA samples extracted from nasopharyngeal swab 612 (NPS) specimens with Cq< 30 chosen at random. (A) Identification of SARS-CoV-2 positive 613 614 samples, and the SNV N501Y, K417N/T, E484K, Hv 69/70 del, and/or P681H. From the twelve 615 samples, only the single identification of SARS-CoV-2 was registered on six samples. The other six 616 samples were SARS-Cov-2 positive and also positive for the SNV N501Y, K417N/T, and E484K. 617 None of the samples were positive for SNV Hy 69/70 del, and/or P681H. (B) Cq mean \pm standard 618 deviation (mean \pm SD) for the SARS-CoV-2 gene amplification obtained by each one of the RT-619 qPCR assessed (red: Thermo Fisher; blue: BGI; Green: Roche).

620

Supplementary Fig 1. Standard amplification curves to determine the probe efficiency and 621 622 detection limit for the Thermo Fisher, BGI, and Roche RT-qPCR kits. The left and right column show the amplification for the reference and the SARS-CoV-2 gene, respectively. The 623 624 analysis included 10-fold serial dilutions from a reference pool made from randomized ten total 625 RNA NPS-extracted samples with a Cq value around 20. The reactions were carried out in triplicate 626 according to the specific conditions indicated by the manufacturer. (A) Amplification curve using the RNase P probe (Thermo Fisher RT-qPCR kit). (B) Amplification curve using the SARS-CoV-2 627 628 ORF1ab probe (Thermo Fisher RT-qPCR kit). (C) Amplification curve using the beta-actin probe 629 (BGI RT-qPCR kit). (D) Amplification curve using the SARS-CoV-2 ORF1ab probe (BGI RTaPCR kit). (E) Amplification curve using the ORF1ab probe (Thermo Fisher RT-qPCR kit; reaction 630 631 mix prepared with the Roche RT-qPCR kit). (F) Amplification curve using the SARS-CoV-2 RdRP 632 probe (Roche RT-qPCR kit). All the graphs represent the linear equation (y = a + bx, b = slope and 633 a = y-intercept), R-suared (R²), and the percentage probe efficiency (%Eff). The dotted line 634 indicates the Cq value at which the detection limit was set for each probe assessed for Thermo 635 Fisher (Cq_{RNaseP}=.36.92; Cq_{ORF1ab}=.37.15), BGI (Cq_{beta-actin}=.38.44; Cq_{ORF1ab}=.35.07), and Roche RT-636 qPCR kit (Cq_{RNaseP}=.38.11; Cq_{ORF1ab}=.35.65).

637

Supplementary Fig 2. Amplification performance for the samples included in the detection of 638 639 SARS-CoV-2 single nucleotide variants (SNV). Total RNA extracted from nasopharyngeal swab (NPS) samples (n= 12) with Cq< 30 chosen at random were screened using three different RT-640 641 qPCR kits (Thermo Fisher (red); BGI (blue); Roche (green)). The comparison was made from the 642 same NPS sample using the optimized volume of total RNA extracted (2 μ l). In the graphs, each 643 spot for each RT-qPCR kit is a different analyzed sample. The line linking the spots indicated the 644 paired result obtained for the same sample assessed by the different RT-qPCR kits. (A) Paired 645 quantification cycle (Cq) analysis for the RNase P amplification values obtained by RT-qPCR for 646 each sample assessed. (B) Cq mean \pm standard deviation (mean \pm SD) for the RNase P 647 amplification obtained by RT-qPCR for all the samples evaluated. (C) Paired relative fluorescence 648 unit (RFU) analysis for the RNase P amplification values obtained by RT-qPCR for each sample 649 assessed. (D) RFU mean ± standard deviation (mean ± SD) for the RNase P amplification obtained 650 by RT-qPCR from all the samples evaluated. (E) Paired Cq analysis for the SARS-CoV-2 ORF1ab gene amplification values obtained by RT-qPCR for each sample assessed. (F) Paired RFU analysis 651 652 for the SARS-CoV-2 ORF1ab gene amplification values obtained by RT-qPCR for each sample 653 assessed. (G) RFU mean \pm standard deviation (mean \pm SD) for the SARS-CoV-2 ORF1ab gene 654 amplification obtained by RT-qPCR for all the samples evaluated. (▲): positive identification of 655 SARS-CoV-2 positive but no one of the SNV assessed (N501Y, K417N/T, E484K, Hv 69/70 del, P681H). (I): positive identification of SARS-CoV-2, and also the SNV N501Y, K417N/T, and 656 657 E484K. The positive identification of these SNV are suggested for the presence of the P1 SARS-

- 658 CoV-2 variant in the sample. For statistical analysis, paired two-sided Student T-test was applied
- 659 (n= 90 NPS samples chosen at random). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.001.

660











Positive samples



